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        Vascular endothelial growth factor (VEGF; vas-
cular permeability factor) is required during em-
bryogenesis for vasculogenesis, the de novo 
formation of blood vessels from hemangioblasts, 
and for angiogenesis, the formation of new ves-
sels from existing vessels (  1  ). Moreover, vascu-
lar development is dependent on tight regulation 
of VEGF, as mice lacking a single   VEGF   allele 
die by embryonic day 8.5 with severe vascular 
defects ( 2, 3 ). Similarly, overexpression of  VEGF   
results in embryonic lethality (  4  ). In the adult, 
VEGF is required for physiological angiogene-
sis, including tissue repair (  5  ) and female re-
production ( 6  ). It also mediates vessel proliferation 
in many pathologies, including age-related mac-
ular degeneration, diabetic retinopathy, and 
cancer (  7, 8  ). 
  In vitro studies have shown that VEGF is re-
quired for endothelial cell (EC) survival (  9  ) and 
can mediate the formation of fenestrations (  10  ). 
Furthermore, in vivo analysis points to a role 
for VEGF in the maintenance of a fenestrated 
EC phenotype (  11, 12  ). Consistent with this, 
VEGF is expressed by the retinal pigmented 
epithelium adjacent to the choriocapillaris (  13  ), 
by podocytes bordering the glomerular endo-
thelium, and by choroid plexus (CP) epithe-
lium abutting the CP microvasculature (  14  ). 
In addition to the emerging function for VEGF 
in mature ECs, in vitro and in vivo studies in-
dicate that VEGF also acts on several nonvascular 
cells, including immune cells and neural cells (for 
reviews see references   15, 16  ). 
  Given the role of VEGF in tumor growth 
and metastasis, drugs targeting VEGF have be-
come part of many antitumor therapies. Al-
though the fi  rst FDA-approved anti-VEGF 
agent, bevacizumab (Avastin; Genentech), im-
proves survival in patients with metastatic co-
lorectal cancer and small cell lung carcinoma, 
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  Although the role of vascular endothelial growth factor (VEGF) in developmental and 
pathological angiogenesis is well established, its function in the adult is less clear. Similarly, 
although transforming growth factor (TGF)      is involved in angiogenesis, presumably by 
mediating capillary (endothelial cell [EC]) stability, its involvement in quiescent vasculature 
is virtually uninvestigated. Given the neurological fi  ndings in patients treated with VEGF-
neutralizing therapy (bevacizumab) and in patients with severe preeclampsia, which is 
mediated by soluble VEGF receptor 1/soluble Fms-like tyrosine kinase receptor 1 and 
soluble endoglin, a TGF-     signaling inhibitor, we investigated the roles of VEGF and TGF-     
in choroid plexus (CP) integrity and function in adult mice. Receptors for VEGF and TGF-     
were detected in adult CP, as well as on ependymal cells. Inhibition of VEGF led to de-
creased CP vascular perfusion, which was associated with fi  brin deposition. Simultaneous 
blockade of VEGF and TGF-     resulted in the loss of fenestrae on CP vasculature and thick-
ening of the otherwise attenuated capillary endothelium, as well as the disappearance of 
ependymal cell microvilli and the development of periventricular edema. These results 
provide compelling evidence that both VEGF and TGF-     are involved in the regulation of 
EC stability, ependymal cell function, and periventricular permeability. 492 VEGF AND TGF-     IN THE MAINTENANCE OF THE CHOROID PLEXUS | Maharaj et al.
    RESULTS   
  VEGF, TGF-    1, and their receptors in adult mouse CP 
and ependyma 
  A prerequisite for VEGF and/or TGF-     to play a role in main-
tenance of the CP is the expression of both the receptor and li-
gand. Given that VEGF is robustly expressed in the CP epithelium 
(  14  ) and that TGF-    1 has been immunolocalized in the CP 
(  34  ), we sought to determine the expression of VEGFR2, 
TGF-    1, and TGF-    R2 in the CP. RT-PCR of CP dissected 
from adult mice revealed the expression of VEGFR2 and 
TGF-    R2, as well as TGF-    1 (  Fig. 1 A  ).   Analysis of VEGF 
isoforms by real-time RT-PCR showed   VEGF120  , which is 
freely diff  usible, as the predominant isoform (52.6%), followed 
by  VEGF164   (45.6%), and very low levels (1.7%) of  VEGF188   
(  Fig. 1 B  ). The high proportion of the soluble form of VEGF 
motivated us to examine the localization of VEGFR2, the pri-
mary signaling receptor of VEGF. Immunohistochemistry of 
  VEGF-lacZ   mouse brain sections revealed VEGFR2 expression 
in the CP vasculature (  Fig. 1 C  , black arrows) underlying the 
VEGF-expressing CP epithelium (arrowheads). Unexpectedly, 
we also found VEGFR2 to be expressed by ependymal cells 
lining the ventricles (  Fig. 1 C  , red arrows). Immunohisto-
chemistry also revealed TGF-    R2 on CP epithelial cells and 
ependymal cells (  Fig. 1 D  , arrows and arrowheads, respec-
tively). The presence of both ligands and receptors for VEGF 
and TGF-     is consistent with a role for these factors in CP and 
ependymal cells. 
  Neutralization of VEGF or VEGF and TGF-     results in CP 
vasculature and ependymal cell defects 
  To determine the function of VEGF and TGF-     in the CP, 
we injected adult mice intravenously with adenovirus (Ad)-
sFlt1 or Ad-sEng, a combination of Ad-sFlt1 + Ad-sEng, or 
Ad-null using previously described Ad constructs and titers 
(  32  ). Plasma sFlt1 and sEng levels of     200 ng/ml were deter-
mined by ELISA 7 d after injection and were sustained for at 
least 21 d for sFlt1 and 14 d for sEng (unpublished data). 
  To determine the eff  ects of neutralizing VEGF and/or 
TGF-     on CP vascular blood fl  ow, mice were perfused with 
high mol wt FITC-dextran after 14 d of infection. Immuno-
staining of brain sections for type IV collagen (coll IV;   Fig. 2 A  ), 
which as a component of the vascular basement membrane 
outlines all blood vessels (  35  ), revealed 95.2% (  n   = 5) co-
localization with FITC-dextran in Ad-null  –  expressing mice 
(  Fig. 2, A and B  ).   Perfusion of the CP vasculature was not 
signifi  cantly altered by the expression of Ad-sEng (92%; 
P = NS;   n   = 6;   Fig. 2 B  ). There was a signifi  cant decrease in 
the perfusion of the CP vessels in mice expressing sFlt1 
(73.3%; P   <   0.02;   n   = 6;   Fig. 2 B  ) and in mice expressing 
sFlt1 + sEng (72.6%; P   <   0.001;   n   = 6;   Fig. 2 B  ). Hematoxy-
lin and eosin (H + E) staining (  Fig. 2 C  ) and immunohisto-
chemical localization of fi  brinogen, as a surrogate for fi  brin 
deposition as previously described (  Fig. 2 D  ) (  36  ), in serial 
sections revealed multiple thrombi in Ad-sFlt1 and Ad-sFlt1 + 
Ad-sEng mice (arrows) but not in Ad-null  –   or Ad-sEng  –  ex-
pressing mice. 
consistent side eff  ects include hypertension, proteinuria, and 
thrombosis, indicating that systemic VEGF blockade leads to 
vascular and tissue dysfunction (  17  –  19  ). 
  Similar conclusions come from observations of preeclampsia. 
Preeclampsia (for review see reference   20  ), a disease of preg-
nancy that aff  ects 4  –  5% of women beginning in the second 
trimester, is mediated by elevated levels of placenta-derived 
factors that lead to systemic endothelial dysfunction, with 
symptoms including hypertension and proteinuria. Among the 
factors overexpressed in preeclampsia is soluble VEGFR1/
soluble Fms-like tyrosine kinase receptor 1 (sFlt1), an endogenous 
VEGF inhibitor. The administration of sFlt1 to pregnant rats 
leads to hypertension, proteinuria, thrombosis, and glomerular 
injury (  21  ), all of which are observed in both preeclampsia and 
in patients treated with bevacizumab (  22  ). 
  Untreated, preeclampsia may progress to eclampsia, which 
is marked by severe central nervous system (CNS) symptoms, 
including headaches, altered mental status, blurred vision, 
blindness, seizures, and stroke. Brain magnetic resonance im-
aging (MRI) of severely preeclamptic women reveal lesions 
characteristic of reversible posterior leukoencephalopathy 
syndrome (RPLS) (  23  ). Interestingly, RPLS has also been re-
ported in bevacizumab-treated patients (  24, 25  ). RPLS is as-
sociated with several vascular disorders, including eclampsia, 
thrombotic thrombocytopenic purpura, and cyclosporine 
toxicity, and it is believed that a primary insult to the endo-
thelium may underlie the neurological fi  ndings. The notion 
that VEGF neutralization might directly aff  ect the brain is 
supported by observations of VEGF expression in the adult 
brain, with particularly high expression in the CP (  14  ). 
  VEGF expression is regulated by a variety of growth fac-
tors, including TGF-     (  26  ). Contact between ECs and mural 
cells in vitro leads to the local activation of latent TGF-    , 
which acts on ECs and pericytes, causing a wide range of ef-
fects, including the inhibition of endothelial proliferation and 
migration (  27, 28  ), induction of mural cell diff  erentiation, 
and pericyte production of VEGF (  9  ). TGF-     also stimulates 
VEGF production by several other cell types, including epi-
thelial cells (  29  ), macrophages (  30  ), and osteoblasts (  31  ). 
  Soluble endoglin (sEng), a circulating TGF-     signaling in-
hibitor, is also elevated in the serum of preeclamptic patients 
(  32, 33  ). sEng, the proteolytically cleaved extracellular domain 
of the TGF-     coreceptor Eng (CD105), can neutralize free 
TGF-    1 and TGF-   3. Coexpression of sEng and sFlt1 in preg-
nant rats increases the severity of the phenotype (as compared 
with sFlt1), including hypertension, proteinuria, permeability, 
thrombocytopenia, and liver and kidney damage, all of which 
are associated with severe preeclampsia (  20  ). 
  Based on our previous observations of VEGF expression 
in the CP (  14  ), as well as clinical fi  ndings of CNS symptoms, 
including RPLS in preeclamptic/eclamptic patients, we hy-
pothesized that VEGF and TGF-     are required for the stability 
and maintenance of the CP and that blockade of these mole-
cules would result in CNS damage. We report the eff  ects of 
VEGF and TGF-     neutralization in the CP and ependyma of 
adult mice. JEM VOL. 205, February 18, 2008 
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  Apoptosis is tightly regulated through several gene prod-
ucts, including members of the Bcl-2 family of genes in the 
CP (  37  ). We examined the relative levels of messenger RNA 
for the   Bcl-2   family in the CP. When compared with Ad-
null, the CP from both Ad-sEng  –   and Ad-sFlt1  –  expressing 
mice expressed signifi  cantly less antiapoptotic   Bcl-x  L     (0.64   ±   
0.11 and 0.74   ±   0.04, respectively; P   <   0.05;   n   = 4), whereas 
Ad-sFlt1 + Ad-sEng had signifi  cantly less antiapoptotic   Bcl-x  L     
and   bcl-2   (0.4   ±   0.13 and 0.58   ±   0.09, respectively; P   <   0.05;   
n   = 4;   Fig. 2 E  ). No change in proapoptotic   bax   or   bad   gene 
expression was detected in any of the groups. 
  Transmission electron microscopy (TEM) of the fenestra-
tions in CP vasculature revealed near complete loss of endo-
thelial fenestrae and swelling of the ECs of mice expressing 
sFlt1 + sEng but no signifi  cant change in mice expressing Ad-
null, Ad-sFlt1, or Ad-sEng (  Fig. 3, A and B  ).   Ultrastructural 
analysis revealed the loss of microvilli on ependymal cells in 
mice expressing Ad-sFlt1 + Ad-sEng for 14 d (  Fig. 3 C  , arrows) 
but not in mice expressing Ad-null, Ad-sFlt1, or Ad-sEng for 
14 d. Although microvilli were absent from mice expressing 
sFlt1 + sEng, the mitochondrial localization and nuclei of 
the ependymal cells appeared relatively normal (  Fig. 3 C  ). 
Collectively, the results of the perfusion analysis and ultrastruc-
tural features indicate that VEGF and TGF-     are required for 
stability of the CP endothelium and for maintaining the in-
tegrity of the ependymal lining of the ventricle. 
  Neutralization of VEGF and TGF-     results in cortical 
periventricular focal lesions 
  Focal contrast enhancement associated with leukoencepha-
lopathy is observed in preeclamptic patients who progress to 
eclampsia, as well as in some patients treated with bevaci-
zumab (  23  –  25  ), and arises from barrier dysfunction and local 
changes in permeability. Based on TEM fi  ndings, we hypoth-
esized that the decreased vascular perfusion and loss of epen-
dymal cell microvilli observed with the inhibition of VEGF 
and TGF-     might compromise the ventricular function. 
To test this, we measured extravasated Evans blue in mice af-
ter 3 d of Ad infection. Mice expressing sFlt1 + sEng, but none 
of the other groups, showed a signifi  cant increase in Evans 
blue extravasation (OD  620nm   = 0.218   ±   0.09 vs. 0.045   ±   0.044 
for Ad-null; P   <   0.05;   n   = 3 and 4, respectively;   Fig. 4 A  ).   
  H + E  –  stained sections of the lateral ventricles revealed 
periventricular edema in mice expressing sFlt1 + sEng at 14 d 
(arrows) but not in other experimental groups (  Fig. 4 B  ). 
To more precisely defi  ne the extent of increased permeability, 
experimental mice were subjected to MRI with gadopen-
tetate dimeglumine (Gd) contrast after 8 and 16 d of infection. 
Gd does not cross the intact blood  –  brain barrier and, thus, is 
a direct marker for blood  –  brain barrier disruption (  38  ). In this 
study, a high dose of Gd (0.3 mM/kg body wt) was used to 
maximize detection. T1-weighted MRI on mice infected for 
8 (  Fig. 4 C  ) or 16 (  Fig. 4 D  ) d revealed lesions surrounding the 
lateral ventricle in the midbrain in animals expressing sFlt1 
and sEng but not in other groups. Quantifi  cation of the peri-
ventricular lesion signal intensity revealed a signifi  cant increase 
    Figure 1.         Expression of VEGF, TGF-        1, VEGFR2, and TGF-        R2 
in the CP and ependyma.   (A) RT-PCR of complementary DNA from 
CP dissected from the lateral third and fourth ventricles of four adult 
mice (  n   = 3 pools) revealed expression of TGF-    1 and its receptor, 
TGF-    R2, as well as VEGFR2. (B) Real-time RT-PCR of CP comple-
mentary DNA (  n   = 4 pools) for VEGF isoforms (52.6%   VEGF120,  
45.5%   VEGF164  , and 1.8%   VEGF 188  ). (C) Staining of   VEGF-lacZ   brain 
sections for   lacZ   (blue) and AEC immunostaining for VEGFR2 (red) 
revealed VEGFR2 in the CP vasculature (black arrows) adjacent to 
VEGF-expressing CP epithelial cells (arrowheads) and in the ependy-
mal lining of the ventricle (red arrows). (D) DAB immunostaining 
  followed by hematoxylin staining of adult brain sections for TGF-   R2 
reveals TGF-    R2 immunoreactivity in the CP epithelia (arrows) and 
ependyma (arrowheads). E, ependyma; P, parenchyma; V, ventricle. 
Bars, 50    m.   494 VEGF AND TGF-     IN THE MAINTENANCE OF THE CHOROID PLEXUS | Maharaj et al.
    Figure 2.         VEGF neutralization results in decreased CP vascular perfusion and fi  brin deposition.   (A) Mice perfused with high mol wt fl  uorescein 
dextran show a signifi  cant decrease in vessel perfusion in Ad-sFlt1 as well as in Ad-sFlt1 + Ad-sEng mice (arrows). Nonperfused vessels are identifi  ed 
as coll IV positive (red) and fl  uorescein negative. (B) Perfused blood vessels were quantifi  ed by measuring the proportion of sectional area occupied by 
fl  uorescein (green) and coll IV fl  uorescence (red; adapted from reference   63  ). Results represent the mean value of three sections 150     m apart per mouse, 
and the mean of fi  ve to six animals. (C) H + E staining (black arrows) and (D) immunofl  uorescent staining (white arrows) for fi  brinogen in CP show 
 multiple  fi  brin clots in Ad-sFlt1 (C and D, arrows) and Ad-sFlt1 + Ad-sEng (C and D). (E) Relative messenger RNA expression of proapoptotic (  bad   and   bax ) 
and antiapoptotic (  Bcl-2   and   Bcl-x  L   ) genes in CP were determined by real-time PCR analysis. Bars: (A and C): 50     m; (D) 25    m.   JEM VOL. 205, February 18, 2008 
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  Because RPLS has also been reported in association with 
bevacizumab treatment (  24, 25  ), mice expressing Ad-sFlt1 or 
Ad-null for 28 d were imaged with MRI. There were no 
brain changes in mice expressing Ad-sFlt1 at days 8 or 16; 
in contrast intensity (day 8, 1.12 for Ad-sFlt1 + Ad-sEng vs. 
1.02 for Ad-null [P   <   0.001;   n   = 6]; and day 16, 1.17 for 
Ad-sFlt1 + Ad-sEng vs. 1.01 for Ad-null [P   <   0.0001;   n   = 7]; 
  Fig. 4 D  ). 
    Figure 3.         Effect of VEGF and TGF-         neutralization on the ultrastructure of CP vasculature and the ependyma.   After 14 d of infection with the 
indicated Ad  ’  s, the CP and ependyma were examined by TEM. (A) In the CP vasculature, fenestrations (arrows) were unaffected in Ad-null, Ad-sFlt1, and 
Ad-sEng mice, whereas mice expressing Ad-sFlt1 + Ad-sEng exhibited loss of fenestrations, increased EC thickening (vertical bar), and the appearance of 
multiple caveolae (arrows). (B) Quantifi  cation of the number of fenestrations per 1     m revealed no signifi  cant change between Ad-null (3.6   ±   0.37; 
  n   = 5), Ad-sFlt1 (3.22   ±   0.2;   n   = 3), and (Ad-sEng (3.53   ±   0.43;   n   = 5), whereas only 1.17   ±   0.41 (P   <   0.05;   n   = 6) were present in Ad-sFlt1 + Ad-sEng  –  treated 
mice CP. (C) Electron microscopic visualization of the ependymal cells in all experimental groups revealed normal apical polarity of the mitochondria 
(labeled M). Dashed lines indicate the cell  –  microvilli border, arrows indicate microvilli, and arrowheads indicate cilia. Bars: (A) 1.25     m; (C) 2.5    m.   496 VEGF AND TGF-     IN THE MAINTENANCE OF THE CHOROID PLEXUS | Maharaj et al.
    Figure 4.         Effect of VEGF and TGF-         neutralization on brain permeability.   (A) Experimental mice infected for 3 d were injected intravenously with 
2% Evans blue in PBS. After 40 min, the brains were removed and quantifi  ed for Evans blue/albumin leakage. Simultaneous treatment with sFlt1 + sEng (  n   =  3) 
resulted in signifi  cantly increased Evans blue leakage into the extravascular space, whereas no changes could be detected with sFlt1 or sEng alone. Values 
represent means   ±   SD. (B) H + E staining of sections of the lateral ventricle of mice expressing sFlt1 + sEng for 14 d revealed marked periventricular 
edema (arrows) below the ependyma (arrowheads); no edema was observed in this region in other experimental or control mice. V, ventricle. Bar, 25    m. 
(C and D) T1-weighted coronal MRI of experimental mice intravenously injected with Gd at 8 (C) and 16 (D) d after infection revealed focal lesions surrounding 
the lateral ventricles in the midcortex of mice expressing sFlt1 + sEng (white arrows) but not in the other experimental groups. (E) Quantifi  cation of the 
ratio of signal intensity in the periventricular zone versus the nonenhancing region in the cortex using ImageJ software (NIH). Values represent means   ±   SEM.     JEM VOL. 205, February 18, 2008 
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been reported in the kidney after VEGF neutralization (  12, 43  ) 
and in the choriocapillaris following intravitreal bevacizumab 
treatment after 4 d (  11  ), we only observed a minimal loss of 
fenestrations in the CP following systemic VEGF neutralization 
after 7 d, in contrast to a near complete loss of CP fenestrations 
in animals treated with sFlt1 + sEng. Plasmalemmal vesicle – 
associated protein has been shown to be associated with 
diaphragmmed fenestrae (  46  ) and to be up-regulated by VEGF 
(  47  ). Although high PV-1 levels are found in several fenes-
trated vascular beds, PV-1 is not detectable in whole brain ex-
tracts (  46  ). Consistent with this observation, we did not detect 
PV-1 in the CP (unpublished data). We speculate that although 
VEGF has been shown to induce fenestrations in cultured ECs 
(  10, 48  ), fenestrations lacking PV-1, such as those found in the 
CP, may be determined by both VEGF and TGF-     signaling. 
  After inhibition of TGF-    1 or VEGF, we observed de-
creased antiapoptotic   Bcl-x  L     expression, whereas combined 
TGF-    1/VEGF inhibition decreased both   Bcl-2   and   Bcl-x  L     
expression. No change was detected in the proapoptotic markers 
  bax   or   bad.   Because antiapoptotic Bcl-2 proteins often func-
tion by binding proapoptotic Bcl-2 family members, a de-
crease in a single Bcl-2 family member is suffi   cient to trigger 
apoptosis (  49, 50  ). Our fi  ndings suggest that both VEGF and 
TGF-     enhance survival through the Bcl-2 family genes. 
  Our results reveal ependymal cells as novel targets for 
VEGF and TGF-    . Ependymal microvilli are central to main-
taining homeostasis and the transport of cerebrospinal fl  uid 
(CSF) through the ventricles (  51  ); furthermore, enzymes lo-
calized to the microvilli mediate signaling and transport of 
molecules between the CSF and ependyma (  52  ). Ependymal 
cells express TGF-    R2 during development (  53  ), but the 
  action of TGF-     on these cells in the adult has not been 
  reported. A previous study of VEGFR2 on ependymal cells 
in vivo proposed that paracrine signaling of VEGF on epen-
dymal cells is important for stimulation of adult neural stem cells 
and neurogenesis (  54  ). We extend this observation by dem-
onstrating that CP epithelial cells predominantly express the 
soluble VEGF120 isoform, which is presumably secreted into 
the CSF, as VEGF is detectable in normal CSF (  54  ). As si-
multaneous neutralization of TGF-     and VEGF led to a loss 
of microvilli on the ependymal cells but did not aff  ect perfu-
sion of periventricular blood vessels (unpublished data), it seems 
likely that disruption of the ependymal barrier altered the 
homeostasis of the surrounding tissue, leading to loss of peri-
ventricular vasculature barrier function (  55  ). 
  RPLS has been reported in some bevacizumab-treated pa-
tients and has been associated with primary vascular disorders 
such as eclampsia, thrombotic thrombocytopenic purpura, and 
cyclosporine toxicity (  56  ). VEGF neutralization for 28 d, or 
VEGF and TGF-    1 neutralization for 8 or 16 d led to the 
development of similar focal lesions. RPLS has been specu-
lated to be secondary to factors such as hypertension (  23  ). Al-
though blood pressure was elevated at day 7 in mice expressing 
sFlt1 + sEng (  Fig. 5 C  ), the increase was modest, making it a 
less likely cause of the observed MRI lesions. Furthermore, 
although sEng expression resulted in an increase in blood 
however, signifi  cant periventricular lesions were detected after 
28 d of VEGF neutralization (Ad-null, 1.062 [ n   = 4] vs. Ad-sFlt1, 
1.135 [  n   = 5]; P   <   0.02;   Fig. 5 A  , arrows; and quantifi  ed in 
  Fig. 5 B  ), providing support that extended VEGF blockade 
may result in RPLS.   These mice displayed only a modest in-
crease in mean arterial blood pressure at day 7 (  Fig. 5 C  ). 
    DISCUSSION   
  We used Ad  ’  s expressing soluble receptors for VEGF (sFlt1) 
and TGF-    1 and TGF-    3 (sEng) to determine the eff  ects 
of VEGF and TGF-     neutralization in adult mice. Immuno-
histochemical analysis and RT-PCR revealed expression of 
both VEGFR2 and TGF-    R2 in the CP, as well as on the 
ependymal cells that line the ventricles. The presence of both 
ligands and receptors implies a role for these growth factors in 
the CP and ependyma. 
  Neutralization of VEGF in adult mice for 14 d resulted in 
decreased perfusion of the CP vasculature associated with mi-
crothrombosis. The simultaneous neutralization of TGF-     
did not lead to an increase in capillary nonperfusion over the 
time period examined. The loss CP vascular fenestrations of 
ependymal cell microvilli in mice expressing sFlt1 + sEng for 
14 d implies that VEGF and TGF-     are similarly required for 
the maintenance of this cellular specialization. Permeability 
studies revealed periventricular focal lesions in mice in which 
VEGF and TGF-     were neutralized for 8 or 16 d, as well as 
in mice in which VEGF was neutralized for 28 d, suggesting 
that growth factor neutralization is suffi   cient to disrupt ven-
tricular barrier function. 
  The role of TGF-     signaling in angiogenesis is context 
dependent, with reported actions both as a pro- and anti-
angiogenic stimulus (  39, 40  ). Cultured ECs treated with TGF-     
are typically growth arrested. Expression of Eng by ECs is 
greatly increased during angiogenesis and in multiple tumors 
(  41  ). Mutations in Eng or the EC-specifi  c TGF-     receptor 
TGF-    RI (activin receptor  –  like kinase 1) cause hereditary 
hemorrhagic telangiectasia 1 and 2, respectively, which are 
characterized by vascular malformations, suggesting a role for 
TGF-     signaling in vascular formation and/or stabilization. 
  Observations from this study add to the growing body of 
evidence that VEGF is critical to vessel stability and that neutral-
ization may lead to microvascular damage (  12, 21, 35, 42, 43  ). 
Disrupted vascular perfusion and fi  brin accumulation in the 
CP is reminiscent of the cerebral changes noted in preeclamp-
sia (  44  ). Although VEGF neutralization is also associated with 
thrombosis in bevacizumab-treated patients (  18  ), the mecha-
nism is not known. Thrombosis may be initiated by the injury 
or activation of the endothelium and/or by a change in the 
balance of pro- and antithrombotic factors. We did not detect 
activated P-selectin or     IIb    III on the platelets of mice ex-
pressing sFlt1 (unpublished data); thus, platelet activation is 
unlikely to be the basis of the observed thrombosis. 
  We observed that VEGF and TGF-     neutralization led to 
the loss of CP vessel fenestrations. Fenestrations are pore-like 
endothelial specializations, which may be diaphragmmed or 
nondiaphragmmed (  45  ). Although decreased fenestrations have 498 VEGF AND TGF-     IN THE MAINTENANCE OF THE CHOROID PLEXUS | Maharaj et al.
TGF-     signaling results in disruption of the CP, which may 
lead to altered CSF dynamics and composition. In addition, 
ependymal cell dysfunction appears to result in disruption of 
ventricular barrier function and altered periventricular homeo-
stasis, which may lead to the neurological manifestations 
observed in preeclampsia/eclampsia, including seizures. 
  Because the CP is the source of CSF, defects in the CP 
are likely to infl  uence CSF production and composition. Ob-
servations of increased hemoglobin (  57  ), protein (  58  ), and 
     hydroxybutyric dehydrogenase (  59  ) in the CSF of severely 
pressure comparable to that noted with sFlt1 + sEng expression, 
no lesions were observed in these mice. Similarly, markers of 
endothelial damage, but not blood pressure, appear to corre-
late with brain edema in patients with preeclampsia/eclampsia 
who present with RPLS (  56  ). Whether the focal lesions are 
reversible after cessation of VEGF and TGF-     neutralization 
remains to be explored. 
  High circulating levels of sFlt1 and sEng in the serum of 
preeclamptic patients appear responsible for many of the asso-
ciated symptoms. Our data suggest that blockade of VEGF and 
    Figure 5.         Effect of long-term VEGF neutralization on brain permeability, and effects of VEGF and TGF-         neutralization on blood pressure.  
(A and B) T1-weighted coronal MRI of Gd intravenously injected mice after 28 d of Ad-sFlt1 or Ad-null expression revealed focal lesions surrounding the 
lateral ventricles of signifi  cant intensity in the midcortex in Ad-sFlt1 mice. Areas in A represent the area of periventricular leakage observed on MRI. 
Values in B represent means   ±   SEM. (C) Noninvasive blood pressure measurement of experimental mice at day 7 Ad expression shows a small difference 
between Ad-null and Ad-sFlt1 mice but a signifi  cant difference between mice expressing Ad-null and Ad-sEng (P   <   0.01) and Ad-sFlt1 + Ad-sEng (P   <   0.01). 
Horizontal bars represent the average of the mean arterial pressure in the different groups.     JEM VOL. 205, February 18, 2008 
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(Jackson ImmunoResearch Laboratories) with nuclear TO-PRO-3   iodide 
stain (Invitrogen) and biotin-conjugated anti  –  rabbit (Vector Laboratories). 
Antibodies were visualized with avidin-biotin peroxidase and 3-amino-
9-ethylcarbazole (AEC) or 3,3    -diaminobenzidine (DAB) substrates (ABC 
kit; Vector Laboratories). For   VEGF-lacZ  , slides were fi  rst stained for LacZ 
using the in situ     -galactosidase kit (Stratagene). 
  TEM.     After 14 d of infection with Ad, mice were perfused as described in 
fl  uorescein perfusion using 10 ml of sodium cacodylate buff  er (0.2 M, pH 
7.4), followed by 10 ml of half-strength Karnovsky  ’  s fi  xative. The third and 
fourth ventricles were dissected and fi  xed with half-strength Karnovsky  ’  s 
fi  xative, followed by 2% osmium tetroxide and en block stain with 0.5% 
uranyl acetate. After dehydration and embedding, ultra-thin sections were 
visualized using a transmission electron microscope (model 410; Phillips). 
  RNA isolation and PCR.     CP from the lateral third and fourth ventricles 
were dissected and pooled from four mice for RNA extraction using the 
RNAqueous-4PCR kit (Ambion). RNA was reverse transcribed using 
  Superscript II (Invitrogen;   Table I  ).   
  For quantifi  cation of VEGF isoform expression, standard curves were 
generated and normalized to 18S using a sequence detection system (Prism 
9700; Applied Biosystems). For pro- and antiapoptotic genes, data were 
  analyzed by the comparative threshold cycle method using GAPDH as an 
endogenous control. 
  Vascular permeability.     Vascular permeability was assessed using Evans blue, 
as previously described (  32  ). After 72 h, mice were anesthetized and injected 
retroorbitally with 2% Evans blue dye. 40 min later, mice were perfused with 
PBS containing 2 mM EDTA for 20 min. Brains were harvested and incubated 
in formamide at 70  °  C for 24 h Supernatants containing extravascular Evans 
blue were collected after centrifugation at 14,000 rpm for 10 min. The OD was 
measured at 620 nm and was corrected for contamination with heme pigments 
using the formula OD  620   (corrected) = OD  620        (1.326   ×   OD  740   + 0.03). 
  For quantifi  cation of endothelial fenestrations, segments of individual 
capillaries were photographed at a fi  nal magnifi  cation of 10,400 (one vessel from 
three to six animals per group). Fenestrations were quantifi  ed per 1     m, and data 
represent the mean of three segments (  ±  SEM) of three to six vessels per group. 
preeclamptic patients supports this hypothesis. CP function may 
also contribute to Alzheimer  ’  s disease, amyotrophic lateral scle-
rosis, and other diseases of the CNS (  60, 61  ), and the fi  nding that 
both VEGF and TGF-     are altered in these diseases is consistent 
with their role in the integrity of the CP and ependyma. 
  MATERIALS AND METHODS 
  Mice.     Mice used included adult   VEGF-lacZ   mice (  62  ) for localization of 
VEGF expression, adult C57B6/J mice for RNA and for permeability ex-
periments, and CD-1 mice. Animal protocols were approved by the Schepens 
Eye Research Institute and Beth Israel Deaconess Medical Center Institu-
tional Animal Care and Use Committees. 
  Mice were injected via the tail vein with Ad  ’  s expressing sFlt1 (Ad-
sFlt1), sEng (Ad-sEng), or empty Ad (Ad-null) as follows: 10  10   viral particles 
(VP) for Ad-CMV-null (control), 2.5   ×   10  9   VP for Ad-CMV-sFlt1, 7.5   ×   
10  9   VP for Ad-CMV-sEng, or 2.5   ×   10  9   VP for Ad-CMV-sFlt1 plus 7.5   ×   
10  9   VP for Ad-CMV-sEng (Qbiogene) (  32  ). Blood pressure was recorded 
on days 7 and 14 by volume pressure recording using a noninvasive blood 
pressure system (CODA 6; Kent Scientifi  c) under 2% isofl  urane anesthesia. 
sFlt1 and sEng plasma levels were determined by ELISA. 
  Fluorescein perfusion.     After 14 d of Ad infection, mice were perfused 
over 2 min with 7 ml of 50 mg/ml of 2   ×   10  6   mol wt fl  uorescein dextran in 
4% paraformaldehyde via a 21-gauge cannula inserted into the aorta via the 
left ventricle, allowing fl  uid to exit via the right atrium. 
  Immunohistochemistry.     Cryosections were cut at 10     m and paraffi   n 
sections were cut at 6     m. Sections were incubated overnight at 4  °  C with 
the following primary antibodies: rabbit polyclonal anti  –  coll IV (1:400; Abcam), 
rat monoclonal anti-CD31 (platelet/EC adhesion molecule 1; 1:100; clone 
MEC 13.3; BD Biosciences), rabbit polyclonal antifi  brinogen (1:250; Dako) 
(  36  ), rabbit anti  –  mouse VEGFR2-T1014 (1:500; a gift from R. Brekken, 
University of Texas Southwestern Medical Center, Dallas, TX), and rab-
bit polyclonal anti  –  mouse TGF-    R2 (1:100; Santa Cruz Biotechnology, 
Inc.) diluted in blocking solution (0.2% Tween, 3% donkey serum, 3% 
goat   serum). Secondary antibodies included cyanine 3  –  donkey anti  –  rabbit 
    Table I.        Mouse primers used in RT-PCR and real-time PCR 
Transcript Primer Sequence Reference
  VEGFR2  5   5    -GCCCTGCTGTGGTCTCACTAC-3    reference   64 
3   5    -CAAAGCATTGCCCATTCGAT-3   
  TGF-   1  5   5    -GCTGCGCTTGCAGAGATTAAA-3    reference   65 
3   5    -TTGCTGTACTGTGTGTCCAG-3   
  TGF-   RII 5   5    -CGTGTGGAGGAAGAACAACA-3    reference   65 
3   5    -TCTCAAACTGCTCTGAGGTG-3   
  VEGF   common forward 5   5    -GCCAGCACATAGAGAGAATGAGC-3    reference   13 
  VEGF 120   reverse 3   5    -CGGCTTGTCACATTTTTCTGG-3    reference   13 
  VEGF 164   reverse 3   5    -CAAGGCTCACAGTGATTTTCTGG-3    reference   13 
  VEGF 188   reverse 3   5    -AACAAGGCTCACAGTGAACGC T-3    reference   13 
  Bax  5   5    -AAGCTGAGCGAGTGTCTCCGGCG-3    reference   66 
3   5    -GCCACAAAGATGGTCACTGTCTGCC-3   
  Bad  5   5    -CCAGTGATCTTCTGCTCCACATCCC-3    reference   66 
3   5    -CAACTTAGCACAGGCACCCGAGGG-3   
  Bcl-2  5   5    -CTCGTCGCTACCGTCGTGACTTCG-3    reference   66 
3   5    -CAGATGCCGGTTCAGGTACTCAGTC-3   
  Bcl-x  L    5   5    -TGGAGTAAACTGGGGGTCGCATCG-3    reference   66 
3   5    -AGCCACCGTCATGCCCGTCAGG-3   
  GAPDH  5   5    -GTGCAAAGTGGAGATGGTGCC-3    reference   67 
3   5    -GATGATGACCCGTTTGGCTCC-3   500 VEGF AND TGF-     IN THE MAINTENANCE OF THE CHOROID PLEXUS | Maharaj et al.
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  MRI.     MRI was performed at days 8, 16, and 28 after infection. Mice were 
positioned inside the magnet immediately after intravenous injection of 
0.3 mmol Gd/kg (Magnevist; Schering AG). Magnetic resonance images were 
acquired with a 4.7-tesla magnet using a transmit-receive, birdcage, volume 
coil with an inner diameter of 35 mm (Bruker BioSpin). T2-weighted im-
ages were acquired covering the entire brain using a fast spin echo sequence 
with the following parameters: recovery time (TR) = 1000 ms, echo time 
(TE) = 6.6 ms, echo train = 8, fi  eld of view (FOV) = 30   ×   30 mm  2  , matrix = 
128   ×   128, slice thickness = 1 mm (gapless), slice orientation = ventrocaudal 
plane, and number of slices = 15 (covering the entire brain). A T1-weighted 
sequence was conducted with identical geometry as described for the T2-
weighted sequence and the following parameters: TR = 500 ms, TE = 11 ms, 
and number of excitations = 4. The T1- and T2-weighted sequences yielded 
an in-plane resolution of 234   ×   234 mm  2  . 
  Statistical analysis.     Data were analyzed by the unpaired Student  ’  s   t   test. 
P   <   0.05 was signifi  cant, and means   ±   SEM are presented. For the Evans blue 
extravasation experiment, data are represented as the mean   ±   SD. 
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